Orphan Drugs: About as Niche as a Flat White
To those beyond the world of biopharma, the term “orphan drug” sounds a bit sad, a bit forgotten. But to those involved in the industry, the superior return on investment, supportive regulatory environment and rates of growth mean that these orphans are anything but tragic. We’ve just published our latest report on the state […]
